Adient Medical

Executive Summary

Adient Medical is a pre-revenue medical device company developing absorbable vascular filters to prevent pulmonary embolism (PE). Its lead product leverages FDA-approved absorbable polymers that provide temporary filtration and then safely resorb, eliminating the need for retrieval procedures and reducing long-term complications associated with permanent metal filters. The company is advancing this device through clinical studies, aiming to address a significant unmet need in PE prevention. Founded in 2018 and headquartered in San Jose, California, Adient Medical operates in a competitive space but differentiates itself with a novel bioresorbable approach. As a private company with limited public disclosures, its progress hinges on successful clinical outcomes, regulatory milestones, and potential strategic partnerships. The company's technology could transform the standard of care for patients at risk of PE, offering a safer alternative to current devices.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Pivotal Clinical Trial60% success
• Q2 2027FDA Breakthrough Device Designation50% success
• Q1 2028Interim Safety and Efficacy Data Readout40% success